重症COVID–19患者における侵襲的人工呼吸管理中のステロイドの投与終了と28日死亡率の関連の検討,後方視的コホート研究(Association between corticosteroid treatment termination during invasive mechanical ventilation and 28–day mortality in severe COVID–19 patients, a retrospective cohort study)

恒光 健史 (Takefumi Tsunemitsu), 鈴木 崇生 (Takao Suzuki), 松本 優 (Masaru Matsumoto)
{"title":"重症COVID–19患者における侵襲的人工呼吸管理中のステロイドの投与終了と28日死亡率の関連の検討,後方視的コホート研究(Association between corticosteroid treatment termination during invasive mechanical ventilation and 28–day mortality in severe COVID–19 patients, a retrospective cohort study)","authors":"恒光 健史 (Takefumi Tsunemitsu), 鈴木 崇生 (Takao Suzuki), 松本 優 (Masaru Matsumoto)","doi":"10.1002/jja2.12694","DOIUrl":null,"url":null,"abstract":"ABSTRACT Aims : To investigate the association between corticosteroid treatment termination during invasive mechanical ventilation and 28–day mortality in severe COVID–19 patients. Method s: The study was a single–center, retrospective cohort study of COVID–19 patients undergoing invasive mechanical ventilation on their scheduled corticosteroid termination day between March 1, 2020, and June 30, 2021. The scheduled corticosteroid termination day was scheduled 10 days after initiation of dexamethasone 6mg orally or 6.6mg intravenously. Patients who terminated corticosteroids during the ventilatory period and did not receive corticosteroids thereafter were defined as the termination group, whereas patients who continued to receive corticosteroids in some form after the scheduled corticosteroid termination day were defined as the continuation group. The primary endpoint was 28–day mortality, and the difference was evaluated using the log–rank test. Results : The 28–day mortality was found to be 61% (14 of 23 patients) in the termination group, which was significantly higher than the 28–day mortality of 22% (5 of 23 patients) in the continuation group (Hazard Ratio: 3.82, 95% CI: 1.37–10.68; p=0.005). Conclusions : In severe COVID–19 patients, corticosteroid termination during invasive ventilation is associated with an increased 28–day mortality.","PeriodicalId":200165,"journal":{"name":"Nihon Kyukyu Igakkai Zasshi","volume":"30 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Kyukyu Igakkai Zasshi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/jja2.12694","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

ABSTRACT Aims : To investigate the association between corticosteroid treatment termination during invasive mechanical ventilation and 28–day mortality in severe COVID–19 patients. Method s: The study was a single–center, retrospective cohort study of COVID–19 patients undergoing invasive mechanical ventilation on their scheduled corticosteroid termination day between March 1, 2020, and June 30, 2021. The scheduled corticosteroid termination day was scheduled 10 days after initiation of dexamethasone 6mg orally or 6.6mg intravenously. Patients who terminated corticosteroids during the ventilatory period and did not receive corticosteroids thereafter were defined as the termination group, whereas patients who continued to receive corticosteroids in some form after the scheduled corticosteroid termination day were defined as the continuation group. The primary endpoint was 28–day mortality, and the difference was evaluated using the log–rank test. Results : The 28–day mortality was found to be 61% (14 of 23 patients) in the termination group, which was significantly higher than the 28–day mortality of 22% (5 of 23 patients) in the continuation group (Hazard Ratio: 3.82, 95% CI: 1.37–10.68; p=0.005). Conclusions : In severe COVID–19 patients, corticosteroid termination during invasive ventilation is associated with an increased 28–day mortality.
重症COVID - 19患者在侵入性人工呼吸管理中终止使用类固醇与28天死亡率之间的关系后视队列研究(Association between corticosteroid treatment termination during invasive mechanical)ventilation and 28—day mortality in severe COVID—19 patients, a retrospective cohort study)
目的:探讨有创机械通气期间终止皮质类固醇治疗与重症COVID-19患者28天死亡率的关系。方法:本研究是一项单中心、回顾性队列研究,研究对象是2020年3月1日至2021年6月30日期间接受有创机械通气的COVID-19患者。预定的皮质类固醇终止日定于地塞米松开始后10天,口服6mg或静脉注射6.6mg。在通气期停用糖皮质激素且此后未接受糖皮质激素治疗的患者被定义为终止组,而在预定的糖皮质激素停用日之后继续以某种形式接受糖皮质激素治疗的患者被定义为继续组。主要终点为28天死亡率,使用log-rank检验评估差异。结果:终止组28天死亡率为61%(23例患者中14例),显著高于继续组28天死亡率22%(23例患者中5例)(风险比:3.82,95% CI: 1.37 ~ 10.68;p = 0.005)。结论:在重症COVID-19患者中,有创通气期间终止皮质类固醇与28天死亡率增加相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信